By: Nancy Schimelpfening
New research suggests GLP-1 medications like Ozempic may help reduce several health risks in addition to treating type 2 diabetes and obesity.
Nancy Schimelpfening is an editor for Healthline Media, Inc. Her articles focus on a variety of health topics, including diabetes management, weight loss, cardiovascular health, and mental health. Nancy's goal is to provide accurate and accessible information to empower readers to make informed decisions about their health.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Nancy Schimelpfening's coverage focuses heavily on health and scientific topics, particularly around diabetes, weight loss, medications, aging, mental health, and heart health. She often cites data in her articles.
When reaching out to Nancy with pitches or expert commentary opportunities, consider offering the latest research findings or insights backed by credible data within the healthcare and pharmaceutical sectors. Topics related to innovative treatments for chronic conditions such as diabetes and osteoarthritis might be of particular interest to her audience.
Given her focus on providing evidence-based information regarding various health issues including but not limited to weight management and mental well-being; outreach should include experts who can provide substantial data-driven insights into these areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .